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Using immunohistologic methods, we studied the expres-
sion of the T-cell receptor {TCR}-associated antigens CD3, 
TCR-P, and TCR-c5 by cutaneous T cells in mycosis fun-
goides {MF} {36 patients} and a variety of inflammatory dis-
eases {16 patients}. Most T cells in the inflammatory diseases 
and patch/plaque mycosis fungoides expressed the immuno-
phenotype characteristic of the vast majority of mature pe-
ripheral T cells: CD3+ TCR-p+ TCR-c5-. In contrast, abnor-
mal CD3/TCR-P antigen expression was seen in 3 of 6 cases 
{50%} of tumor stage mycosis fungoides. Furthermore, we 
were able to document its evolution from the normal pattern 
present in earlier patch/plaque lesions of the two cases in 
T he T-cell antigen receptor (TCR), expressed on the surface of the vast majoriry of peripheral T cells, is a heterodimer composed of a and P subunits. This ap dimer is noncovalently associated with the CD3 (T3, Leu4) antigen complex [1 - 3, reviewed in 4]. A small 
number of CD3+ peripheral blood T cells lack this ap dimer [2] . 
Instead, CD3 is associated with a functionally competent yJ hetero-
dimer TCR [5 -9]. 
Several monoclonal antibodies (MAb) are available that react 
with various subunits of the TCR. Tissue section immunohistology 
with MAb P-F1 and anti-TCRJ1, specific for framework determi-
nants on the TCR-P and TCR-J chains respectively, has shown 
almost all lymphocytes in the T zones of peripheral lymphoid 
organs and inflammatory sites to express the TCR-P chain; a very 
small number of cells in these areas express the TCR-J chain 
[2,3,10,11]. In contrast, almost one-third of peripheral T celllym-
phomas in a large series lacked expression of either TCR-P or J 
chain. The remaining two-thirds of the lymphomas expressed 
TCR-P but not J chain [11] . 
Mycosis fungoides (MF) is a lymphoma composed ofT cells that 
usually express a mature peripheral helper T cell immunopheno-
rype [12,13]. This mature Thelper phenorype is generally shared by 
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which serial biopsies were available for study. Divergence of 
epidermal versus dermal CD3/TCR-P antigen expression 
was seen in 2 of 34 (6%) of biopsies of patch/plaque mycosis 
fungoides but not in inflammatory controls. The TCR-c5+ 
cells were generally rare regardless of diagnosis. We con-
clude that inflammatory skin diseases and most patch/plaque 
mycosis fungoides are typically composed ofT lymphocytes 
that resemble mature peripheral T cells in regard to their 
expression ofTCR-associated antigens. In contrast, aberrant 
patterns ofTCR-associated antigen expression can be seen in 
tumor stage MF, and, more rarely in patch/plaque MF. 
] Invest DermatoI93:116-120, 1989 
the majoriry of lymphocytes in a wide variery of inflammatory skin 
lesions [12,13]. In the current study, skin biopsies ofMF and several 
different benign lymphocytic inflammatory lesions were examined 
immunohistochemically for TCR-associated antigens including 
CD3, TCR-P, and TCR-J chains. The vast majoriry of T cells in 
inflammatory skin lesions and MF expressed the phenorype found 
on most peripheral T cells: CD3+ TCR-P+TCR-J-. An exception 
to this phenorype was seen in two rypes of lesions: 1) in 3 of 6 cases 
of tumor stage MF, the lymphoma cells lacked expression ofTCR-P 
(2 cases) or CD3 (1 case) in addition to TCR-J and 2) in 2 of34 cases 
of patch/plaque MF, intraepidermal T cells lacked TCR-P (1 case) 
or CD3 and TCR P (1 case). These antigens, however, were ex-
pressed by the intradermal T cells. 
MATERIALS AND METHODS 
Forty skin biopsies of MF (36 patients) and 16 biopsies of benign 
lymphocytic inflammatory skin lesions (16 patients) were exam-
ined. Three sequential biopsies (two patch/plaque and one tumor) 
were obtained from each of two MF patients. The number ofbiop-
sies in each diagnostic category were as follows: patch/plaque MF 
(34), tumor MF (6), psoriasis (3), cutaneous lymphoid hyperplasia 
(3), allergic contact dermatitis (2), drug eruption (2), and one each 
of lichen planus, spongiotic dermatitis, lichenoid keratosis, piryria-
sis rubra pilaris, piryriasis lichenoides chronica, and piryriasis li-
chenoides et varioliforrrus acuta (PLEVA). All lesions were diag-
nosed using standard clinical and histologic criteria [13]. Histologic 
features of patch/plaque MF consisted of a lichenoid infiltrate of 
arypical mononuclear cells with epidermotropism. The MF tumors 
contained a deep dermal infiltrate as well. All MF cases contained 
either well-developed Pautrier's micro abscesses or smaller focal in-
traepidermal collections of arypical mononuclear cells in the ab-
sence of spongiosis. All cases of MF were subclassified as {atch/ 
plaque or tumor based on clinicopathologic correlation [14 . 
A portion of each biopsy was frozen, cut, and immunostained 
using a three-stage avidin-biotin-horseradish peroxidase system as 
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Table I. Immunophenotype of T Cells in Mycosis Fungoides and Benign Dermatoses 
Diagnosis 
MF-patch/plaque 
Inflammatory 
MF-patch/plaque 
Inflammatory 
MF-tumor 
MF-tumor 
MF-tumor 
MF-patch/plaque 
MF-patch/plaque 
Number of cases 
30 
14 
2 
21 
2' 
1 
3 
1 
CD3 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
TCR-P TCR-o Location' 
+ 
+ 
+ 10-20%+ 
+ 10-20%+ 
+ 
+ 
Epidermis 
+ Dermis 
NO Epidermis 
+ Dermis 
• Location of T cells only in cases showing discordant phenotype of epidermal versus dermal T cells. 
• One case each of lichen planus and PLEVA. 
, Each parient had two previous patch/plaque MF lesions (included in row 1 of this table) in which the T ce lls were CD3+TCR-p+TCR-o-. 
ND: not determined. 
previously described [15]. A large panel of MAb directed against 
T -lineage differentiation antigens as well as other hematolymphoid 
antigens was applied to each biopsy [3,15]. These antibodies in-
cluded anti-Leu-4, anti-Leu-3a, and anti-Leu-2a (anti-CD3, CD4, 
and CDB, respectively; Becton-Dickinson, Mountain View, CA), 
BF-l (anti-TCR-P chain framework determinant; courtesy of 
Michael Brenner), and TCR-«51 (anti-TCR-«5 chain framework de-
terminant; courtesy of M. Brenner). Primary antibodies were re-
placed with species and isotype matched irrelevant MAb as negative 
controls. Sections of reactive tonsils were used as positive controls 
[3,11]. Positive staining was interpreted to indicate cell surface or 
cytoplasmic expression, or both. 
Sections were examined by light microscopy and the number and 
location ofT cells, as defined by T cell markers including CD2 and 
CDS, was determined. Sequential sections were then evaluated for 
expression of CD3, TCR-P, and TCR-«5 by the T cells. The CD3 
and TCR-P expression was graded as positive (the vast majority ofT 
cells expressing the antigen) or negative «5% ofT cells expressing 
the antigen). The TCR-«5 expression was graded as negative as de-
scribed above or, in the rare cases showing more than 5% TCR-«5+ 
T cells, as the estimated percent (rounded to the nearest 10%) of 
TCR-«5+ cells. In a few cases of MF, the phenotype of the T cells in 
the epidermis differed from that of the T cells in the dermis. In these 
cases, expression of each antigen was evaluated and reported sepa-
rately for the intraepidermal versus the intradermal T cells. 
RESULTS 
The results are summarized in Table I. In almost every biopsy the 
majority of the lymphoid cells were T cells, except for the three 
biopsies of cutaneous lymphoid hyperplasia that contained intrader-
Figure 1. Patch/plaque MF. Expression of the CD3+TCR-p+ phenotype typical of most mature T cells. A: There is a superficial dermal infiltrate of CD3+ 
(Leu4+) tumor cells with epidermotropism (X160). B: The cells also express TCR-P chain (X160). Serial frozen sections. Immunoperoxidase stain with 
methylene blue counterstain. 
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Figure 2. TCR-o+ chain expression by cutaneous T cell infiltrates. A: Biopsy of MF showing rare TCR-o+ cells (arrowheads) . This was the usual finding in 
most of the cases studied (X160). B: Biopsy ofMF showing 10-20% TCR-o+ cells. This was an uncommon finding identified in only 2 of40 MF cases and 2 of 
16 dermatoses (XI60). Immunoperoxidase stain with methylene blue counterstain. 
mal B cell follicles surrounded by large zones ofT cells [16). Thirty-
five biopsies ofMF hada T-helper (CD4+) phenotype, 4 MF lesions 
(from 2 patients) had aT-cytotoxic/suppressor (CD8+) phenotype, 
and 1 MF lesion failed to express either T-subset marker. Variable 
proportions of CD4 + and CD8+ T cells were seen in the inflamma-
tory lesions [12,13,16). 
In all inflammatory lesions and the majority of MF lesions, the T 
cells co-expressed CD3 and TCR-P (Fig 1). Cells expressing TCR-o 
were extremely rare, accounting for less than 1- 2% of the T lym-
phocytes in most biopsies (Fig 2). In 2 cases ofMF, 1 case of PLEVA 
and 1 case of lichen planus, approximately 10-20% of the T cells 
expressed TCR-o (Fig 2). Most CD3+ cells in these 4 cases were 
CD4+CD8-TCR-P+. There was no expression of TCR-o by 
dendritic cells in the epidermis in any case, suggesting that the 
Thy-1+TCR-o+ dendritic cells found in mouse epidermis do not 
have a counterpart in human skin [17). 
Six cases of tumor stage MF were studied. The T cells in biopsies 
of tumor lesions from 2 patients were CD3+TCR-P-TCR-o- (Fig 
3). Two previous patch/plaque MF biopsies were studied from each 
of these 2 patients. In both cases, most of the T cells in the patch/ 
plaque lesions had the CD3+TCR-p+TCR-o- phenotype (Fig 1). In 
the third case of tumor MF, the T cells had a markedly abnormal 
phenotype with loss of most pan T cell markers including CD3 but 
not TCR-p. The cells also failed to express TCR-o chain antigen. 
The T cells in the final 3 cases of tumor MF were CD3+TCR-
P+TCR-O-. 
In 2 cases of patch/plaque MF, the CD3/TCR phenotype of the 
T cells in the epidermis differed from that of the T cells in the 
dermis. In one of these cases, the dermal T cells were CD3+TCR-
P+TCR-o-. The epidermis and dermal -epidermal junction con-
tained numerous T cells, as scattered single cells and small clusters of 
2 - 3 cells, which showed loss of the TCR-P antigen as well as pan T 
cell antigens CD2 and CDS. In the other case, T cells in the dermis 
were CD3+TCR-p+TCR-o-, whereas T cells in an overlying Pau-
trier's microabscess were CD31CR-p-. As the microabscess was 
present on only a few sections and single cell exocytosis was rare, 
the complete phenotype of the epidermal T cells could not be 
determined. 
DISCUSSION 
Early lesions ofMF are often extremely difficult to diagnose because 
their clinical and histologic appearance can resemble that of some 
benign dermatoses. Immunoperoxidase studies using certain MAb 
can sometimes be helpful in making this diagnostic distinction [13). 
The current data, however, suggest that such studies using antibod-
ies against CD3 or TCR would be of limited usefulness in distin-
guishing patch/plaque MF from reactive lymphocytic infiltrates in 
that the majority of T cells in each of these two lesions have the 
phenotype characteristic of most peripheral T -cells (CD3+ TCR-p+ 
TCR-o- ) [2,3,11) . These anti-CD3/TCR antibodies would have 
been useful in making a diagnosis of MF in only 2 of 34 biopsies of 
patch/plaque MF in this study. In these two lesions, T cells within 
the epidermis (but not within the dermis) had an abnormal T cell 
phenotype suggestive of malignancy (CD3+TCR-P- TCR-o- and 
CD31CR-P-). 
Individual components of the TCR-CD3 complex may be 
present in the cytoplasm of maturing thymocytes without other 
components being present [18 - 20]; however, T cells with aberrant 
(discordant) CD3/TCR phenotypes were not seen in the epidermis 
or dermis of any of the 16 benign lymphocytic lesions in this series, 
nor were they seen in prior immunohistologic studies of normal and 
reactive lymphoid tissues [3,11] . 
In contrast to patch/plaque MF, discordant TCR phenotypes 
were present in 3 of 6 MF tumors. Furthermore, 2 cases of tumor 
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Figure 3. Tumor MF. Evolution of an abnormal TCR phenotype (CD3"TCR-P-) with disease progression (same case as Fig 1 biopsied at a later time). A : 
There is retention of CD3 expression by the infiltrating tumor eells (X160). B: In contrast to the earlier biopsy, TCR-P chain expression is now absent (X160). 
Serial frozen sections. Immunoperoxidase stain with methylene blue counterstain. 
MF expressing an abnormal TCR phenotype (CD3+TCR-P-TCR-
c5-) had prior patch/plaque lesions expressing the typical mature 
TCR phenotype (CD3+TCR-p+TCR-c5-). This demonstrates that 
loss ofTCR antigens in MF can occur with progression of disease, as 
has been previously shown for antigens such as CDS, CD3, and 
CD11 [12]. 
The current TCR data, in conjunction with previously published 
immunophenotypic data, suggest that the neoplastic cells of patch/ 
plaque MF tend to resemble mature peripheral helper T lympho-
cytes while the neoplastic cells of tumor MF often resemble those of 
peripheral T cell lymphomas [2,3,11 - 13,21,22]. The CD3-TCR 
discordance has been reported in as much as one third of the latter 
lesions [3,23]. This latter resemblance is also reflected in the cutane-
ous nodule formation, lack of epidermotropism, and propensity for 
extracutaneous involvement shared by patients with tumor MF and 
those with non-MF peripheral T cell lymphomas involving the skin 
[11- 14,21,22]. These findings suggest important differences be-
tween patch/plaque MF and tumor MF that cross clinical, histo-
pathologic, and immunophenotypic boundaries; they may help to 
explain the more aggressive clinical behavior of tumor stage MF 
in terms of a biologic similarity to non-MF peripheral T cell 
lymphomas. 
TCR-c5+ T cells, most of which lack the CD4 and CD8 subset 
markers, are generally rare in the peripheral blood T cell population 
[1,6,8,9]. However, there is wide individual variation (1-18%) in 
the number of peripheral blood lymphocytes that react with 
TCR-c51 [9]. Because recent studies suggest this antibody is a pan-
TCR-c5 marker [9], TCR-c51 + cells should accurately reflect the 
proportion of T cells expressing the TCR-yc5 heterodimer. The 
TCR-c5+ cells were extremely scarce in most of the biopsies exam-
ined in the current study, suggesting that generally there is no 
selective recruitment of these cells to skin lesions. Additional studies 
are warranted, however, because two biopsies of patch/plaque MF 
and the solitary biopsies oflichen planus and pityriasis lichenoides et 
varioliformis acuta that were studied did contain 10-20% TCR-c5+ 
cells. 
The TCR-c5+ cells may playa role in immune surveillance against 
tumors by means of cytotoxic activity [7,8,24] ; however, the rarity 
ofTCR-c5+ cells in most MF lesions suggests they are not typically a 
major host response factor in MF. An exception may be in the 2 cases 
of MF in this study in which 10- 20% of the T cells expressed 
TCR-c5 chain. In these 2 cases, there may be selective recruitment of 
TCR-c5-bearing T cells into the MF lesions. Alternatively, these 2 
patients may have high circulating levels of TCR-c5+ T cells [9]' If 
these cells are in fact important in tumor-related immune responses, 
these 2 patients might be expected to pursue a favorable clinical 
course. 
Interestingly, one of these patients (T)N1oMoBo at diagnosis) is 
alive with limited patch/plaque disease at 10 years after treatment 
with electron beam radiation and topical nitrogen mustard; the 
other (T1NoMoBo at diagnosis) is alive without disease at 6 years 
after treatment with topical nitrogen mustard. However, studies 
comparing the numbers of TCR-c5+ T cells in MF lesions with that 
in each patients' peripheral blood, as well as long-term follow-up of 
additional patients, will be needed to clarify this issue. 
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